Tag: Safety
Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis Dermatology Times Source link
Prolonged use of oral corticosteroids in adults with atopic dermatitis (AD) was associated with a slight uptick in adverse events (AEs), a nested case-control study showed. Based on a million individuals with AD in South Korea, those who experienced AEs were more likely to have been using oral corticosteroids for longer than 90 days compared […]
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, Melinda Gooderham, MSc, MD, FRCPC, presented late-breaking data on the long-term safety and efficacy of delgocitinib for moderate to severe chronic hand eczema (CHE).1 Patients who completed 16 weeks of treatment in DELTA 1 and DELTA 2 were then treated in […]
Topical phosphodiesterase (PF) 4 inhibitor-07038124 treatment of atopic dermatitis (AD) and plaque psoriasis is both efficacious and well-tolerated among patients, according to recent findings.1 The findings were the result of new research conducted to expand upon existing topical medication options for patients with mild-to-moderate AD or psoriasis, especially given the negative systemic adverse events often […]